Addex Therapeutics Ltd American Depositary Shares (ADXN)
Stock · NASDAQ · Health Care
$2.76as of 10/16/2026
Price chart
Active signals
ADXN Signal Track Record
How signals performed across all stocks →What ADXN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 25 | +3.1% | 52% | September 29, 2026 |
| Bollinger Band Breakout | 19 | -11.8% | 26% | April 14, 2026 |
| Volume Spike | 19 | -11.5% | 26% | August 25, 2026 |
| 200-Day Moving Average TouchActive now | 16 | +4.3% | 56% | January 16, 2026 |
| Any 20-session window (baseline) | -4.4% | 36% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ADXN
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 3
Fundamentals
- 1-day range
- $2.65$3.06
- Market cap
- $7.34M
- P/E (trailing)
- —
- P/E (forward)
- -53.00
- EPS (trailing)
- $-0.06
- Dividend yield
- —
- Beta
- 0.79
- Avg. volume
- 138.1K
Addex Therapeutics Ltd American Depositary Shares Competitors
Chosen by industry and closest market cap.
- ADXNAddex Therapeutics Ltd American Depositary Shares$2.76▼ 8.61%Market cap $7.34MP/E —$0.018$0.069
- APUSApimeds Pharmaceuticals US Inc. Common Stock$4.04▼ 7.97%Market cap $7.29MP/E —$1.51$403.1
- BOLTBolt Biotherapeutics Inc. Common Stock$4▼ 5.66%Market cap $7.44MP/E —$3.1$7.2
- MTVAMetaVia Inc. Common Stock$1.26▼ 8.03%Market cap $7.49MP/E —$0.9661$14.85
- MBRXMoleculin Biotech Inc. Common Stock$0.28▼ 24.32%Market cap $7.50MP/E —$0.1614$15.75
- CANFCan-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares$1.76▼ 4.86%Market cap $7.63MP/E —$299$9,000,000
- XTLBXTL Biopharmaceuticals Ltd. American Depositary Shares$1.96▲ 2.62%Market cap $7.05MP/E —$1.6$11.8
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ADXN Addex Therapeutics Ltd American Depositary Shares | $7.34M | — | $2.76 | ▼ 8.61% | $0.018$0.069 |
| APUS Apimeds Pharmaceuticals US Inc. Common Stock | $7.29M | — | $4.04 | ▼ 7.97% | $1.51$403.1 |
| BOLT Bolt Biotherapeutics Inc. Common Stock | $7.44M | — | $4 | ▼ 5.66% | $3.1$7.2 |
| MTVA MetaVia Inc. Common Stock | $7.49M | — | $1.26 | ▼ 8.03% | $0.9661$14.85 |
| MBRX Moleculin Biotech Inc. Common Stock | $7.50M | — | $0.28 | ▼ 24.32% | $0.1614$15.75 |
| CANF Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares | $7.63M | — | $1.76 | ▼ 4.86% | $299$9,000,000 |
| XTLB XTL Biopharmaceuticals Ltd. American Depositary Shares | $7.05M | — | $1.96 | ▲ 2.62% | $1.6$11.8 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 455
- Total value held
- $2.9K
- Institutional holders
- 4
- Unknown301
- Unknown81
- Unknown72
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Addex Therapeutics Reports Q2 2026 Results and Management Changes
Addex Therapeutics announced executive management changes alongside its Q2 2026 earnings report. The company reported sales of $12,650, a decrease from $44,031 in the same period last year. Additionally, the company provided an update on its corporate status during the half-year results release.
Addex Therapeutics Reports Q2 2026 Results and Management Changes. Addex Therapeutics announced executive management changes alongside its Q2 2026 earnings report. The company reported sales of $12,650, a decrease from $44,031 in the same period last year. Additionally, the company provided an update on its corporate status during the half-year results release.